Global Acanthocytosis Chorea Market, By Diagnosis (MRI, CT-Scan, Biopsy and Others) Treatment (Botulinum Toxin, Antidepressants, Antipsychotics and Others), Route of Administration (Oral, Parenteral, Others), End-Users (Clinics, Hospitals, Diagnostic Centers, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Acanthocytosis chorea market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 4.60% in the above-mentioned research forecast period. Increasing prevalence of disease and an increasing number of associated symptoms including seizure among others.
Technological advancements and availability of reimbursement for medical devices also boost up the market growth. Moreover, increasing research and development, increased investment for pharmaceutical industry expansion, and rising healthcare expenditure act as market growth opportunities. But, side effects associated with treatment options and strict regulatory framework, among others, may hamper the acanthocytosis chorea market
Acanthocytosis chorea is a progressive movement disorder that leads to cognitive and behavioral changes. This disorder primarily affects the limb chorea. Moreover, symptoms of Parkinsonism can also be reported. The most common symptoms associated with this disease are Dystonia, which commonly affects the oral region, leading to dysarthria and severe dysphagia. Nearly half of the affected population reported seizures and the associated myopathy can cause distal muscle wasting and weakness. Acanthocytosis chorea can be diagnosed by MRI and CT scan which reveals the atrophy of the caudate nuclei. Moreover, muscle biopsy used for disease diagnosis reveals the atrophic and central nuclei. The genetic tests checks for the mutation in VPS13A gene which encodes for the chorein protein that leads to acanthocytosis chorea. In order to reduce the oro-facio-lingual dystonia symptoms botulinum toxin is used, speech therapy, feeding assistance, splints are also used for treatment of several associated symptoms. Seizure associated with acanthocytosis chorea managed by applying phenytoin, clobazam, valproate, levetiracetam, antidepressants, and antipsychotic medications are also used.
The number of patients suffering from acanthocytosis chorea is increasing worldwide with reported 500-1,000 cases. This patient population depends on advanced treatment options and is expected to provide the market with lucrative growth. It is also estimated that Acanthocytosis Chorea Market is growing with a CAGR of 4.60% in 2020.
This acanthocytosis chorea market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Acanthocytosis Chorea Market Scope and Market Size
Acanthocytosis chorea market is segmented on the basis of diagnosis, treatment, route of administration, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of diagnosis, the acanthocytosis chorea market is segmented into MRI, CT-scan, biopsy and others.
- On the basis of treatment, the acanthocytosis chorea market is segmented into botulinum toxin, antidepressants, antipsychotics and others.
- On the basis of route of administration, the acanthocytosis chorea market is segmented into oral, parenteral and others.
- On the basis of end-users, the acanthocytosis chorea market is segmented into clinics, hospitals, diagnostic centers and others.
- On the basis of distribution channel, the acanthocytosis chorea market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, others.
Acanthocytosis Chorea Market Country Level Analysis
Acanthocytosis chorea market is analysed and market size information is provided by country, treatment, product, site, end-users and distribution channel as referenced above.
The countries covered in the acanthocytosis chorea market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts for the largest market share due to the increasing prevalence of chorea-acanthocytosis and increasing research and development activities. Europe is also expected to grow due to rising initiatives by regulatory agencies and expanding product distribution networks. Asia-Pacific is growing at the fastest pace due to increasing government initiatives to boost the pharmaceutical sector's growth.
Asia-Pacific is expected to account for the largest market share due to rising awareness regarding the advanced treatment options and increasing market players' focus towards the emerging economies.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis : Global Acanthocytosis Chorea Market
Acanthocytosis chorea market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Acanthocytosis Chorea Market Share Analysis
Acanthocytosis chorea market competitive landscape provides details by competitor details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to acanthocytosis chorea market.
The major players covered in the acanthocytosis chorea market are Pfizer Inc., LUPIN, Sun Pharmaceutical Industries Ltd., Lundbeck, Rosemont Pharmaceuticals Limited, CoreRx, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals, Inc., Vibcare Pharma Pvt. Ltd., MODASA Pharmaceuticals Pvt. Ltd., Sanofi, UCB S.A, Dr. Reddy’s Laboratories Ltd., Lannett, Aster Pharma, Aurobindo Pharma USA, Nexus Pharmaceuticals, Upsher-Smith Laboratories, LLC, Allergan, Sandoz International GmbH, Galderma, Ipsen Pharma, among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Customization Available: Global Acanthocytosis Chorea Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.